{"schema_version":"secwatch.filing_event.v1","accession":"0000886744-25-000068","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.491624+00:00","generated_at":"2026-05-17T00:29:29.331828+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Geron Q3 2025 RYTELO revenue $47.2M; net loss narrows to $18.4M; FY25 opex guidance lowered","bullets":["RYTELO net product revenue $47.2M in Q3 2025 (vs $28.2M in Q3 2024); demand down 3% QoQ.","Net loss $18.4M ($0.03/share) compared to $26.4M ($0.04/share) in Q3 2024.","Completed enrollment of 320 patients in Phase 3 IMpactMF trial for imetelstat in myelofibrosis.","FY 2025 operating expense guidance reduced to $250M-260M from prior $270M-285M.","Appointed Ahmed ElNawawi as EVP, Chief Commercial Officer; three other executives added."],"urls":{"canonical":"https://secwatch.observer/filing/0000886744-25-000068","json":"https://secwatch.observer/filing/0000886744-25-000068.json","markdown":"https://secwatch.observer/filing/0000886744-25-000068.md","text":"https://secwatch.observer/filing/0000886744-25-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000088674425000068/0000886744-25-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000088674425000068/gern-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:29:29.331828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}